Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15
- Drug Discovery
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 117698
With this amendment the Parties desire to modify their agreement to address such issue of sales allocation, and also with respect to the allocation of regulatory responsibilities in Canada, the manufacture and supply of Integrilin Product in Canada, and to set forth certain understandings regarding a Phase III clinical trial for Integrilin Product in the setting of acute myocardial infarction or AMI.
INTEGRILIN is indicated for the treatment of patients with an acute coronary syndrome and patients who undergo angioplasty procedures. The acute coronary syndrome indication includes patients with unstable angina and non-Q-wave myocardial infarction, whether they receive medical treatment or undergo angioplasty.
Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.
Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis.
IPSCIO Record ID: 3640
IPSCIO Record ID: 372578
This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.
CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.
Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.
IPSCIO Record ID: 282942
Eptifibatide shall refer to a specific peptide designated by Licensee and known as eptifibatide, which same peptide was known previously as Integrilin or Integrelin, the chemical structure of which is known to Licensor because of the prior business relationship between Licensee and Licensor.
Integrilin is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries).
IPSCIO Record ID: 203519
The Parties wish to terminate Licensors role in the commercialization and manufacturing of INTEGRILIN in and for the Transferring Territory, and to have Licensors existing regulatory approvals and authorizations, contractual rights and responsibilities transferred in an appropriate manner to a new commercial licensee that this Licensee will identify.
This agreement, terminates certain License rights and modifies other certain license rights terms. For the Modification of IP Licenses Granted to Licensee
– the exclusive licenses under the Licensor Patents granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN Products in the relevant country or countries or in the Transferring Territory, as applicable;
– the non-exclusive licenses under the Licensor Patents granted in the Collaboration Agreement with respect to the Manufacture of INTEGRILIN Products shall be exclusive, except as to Licensor and its Affiliates, with respect to the Manufacture of INTEGRILIN Products for distribution, use and/or sale in the relevant country or countries or in the Transferring Territory,
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement shall be exclusive even as to Licensor solely with respect to Commercializing INTEGRILIN
– the non-exclusive licenses to use the Licensor Know-how granted in the Collaboration Agreement with respect to Manufacturing INTEGRILIN Products shall be exclusive, except as to Licensor solely with respect to Manufacturing INTEGRILIN Products in or for the relevant country or countries or in or for the Transferring Territory.
For Certain Copyrights and Trademarks, Licensor grants to Licensee and the New Commercial Licensee an exclusive, perpetual, sublicensable license under Licensors copyrights in all Marketing Materials solely for use in Commercializing INTEGRILIN Products in the Transferring Territory.
The Trademark means all registrations, applications for registration and other rights in and to the INTEGRILIN mark and the APEREXIN back-up mark for the Development, Manufacture and Commercialization of INTEGRILIN Products in or for the Transferring Territory.
The New Commercial Agreement means a definitive agreement between Licensee and a Pharmaceutical Company under which such Pharmaceutical Company is granted a license to INTEGRILIN Products and assumes primary responsibility for the Development and Commercialization of the INTEGRILIN Products in and for the Transferring Territory, and the Manufacture of the INTEGRILIN Products for Development and Commercialization in the Transferring Territory.
IPSCIO Record ID: 328338
For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.
For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.
The Parties are to develop and commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure, and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.
The patents subject matter includes but is not limited to
– Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
– Method of treating restenosis by administrating c-myr antisense;
– Method of Inhibiting collagen synthesis by treating with c-myr antisense;
– Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
– Pharmaceutical compositions for the above methods.
Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.
Clinical Trial Product means a product, appropriate for use in clinical trials, containing a Licensed Compound or placebo, as applicable, in the formulation as determined by Licensee.
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.
IPSCIO Record ID: 255948
Peripheral artery disease is a narrowing of the peripheral arteries serving the legs, stomach, arms and head. (â€œPeripheralâ€ in this case means away from the heart, in the outer regions of the body.) PAD most commonly affects arteries in the legs. Both PAD and coronary artery disease (CAD) are caused by atherosclerosis.
IPSCIO Record ID: 28285
IPSCIO Record ID: 27406
IPSCIO Record ID: 352721
In order to establish Licensor/Manufacturer of Belgium as a preferred supplier of the Product on a commercial basis, Manufacturer shall perform the development and manufacture of the Product in its premises in Belgium according to the terms.
Manufacturer Technical Information shall mean
– unpatented proprietary and confidential technical information, specifications, compositions, manufacturing methods, application methods, testing methods, computer programs,technical data and drawing as well as any improvements thereto.
– patents and patent applications on any of the foregoing, including divisions, owned by, or licensed or assigned to Manufacturer, and based on inventions which are either actually reduced to practice or constructively reduced to practice by filing a patent application on such invention prior to the termination of this Agreement, continuations, continuations in part, extensions, amendments and reissues thereof.
Bivalirudin shall mean the 20 amino acid polypeptide corresponding to LC13 Code Name SP071 and/or SF220.
Chemilog shall mean the process by which Bivalirudin API is manufactured.
Product shall mean the fully chemically synthetized Bivalirudin API either through Manufacturers existing process or the Chemilog Process.
Licensor manufactured two validation batches of Angiomax bulk drug substance using the Chemilog proces.
Angiomax directly blocks or inhibits the actions of thrombin, a key component in
the formation and growth of blood clots.
(Angiomax(R)) and is developing and marketing pharmaceutical compositions containing Bivalirudin for the treatment of PTCA and other diseases.
Angiomax is for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty.
– reduced the frequency of life-threatening coronary events including heart attack and the need for emergency coronary procedures;
– reduced the likelihood of major bleeding and the need for blood transfusion;
– demonstrated a predictable anticoagulant response to a specific Angiomax dose, which enables simplified dosing; and
– been used in combination with GP IIb/IIIa inhibitors and other products used in angioplasty
IPSCIO Record ID: 8745
IPSCIO Record ID: 28946
Bioabsorbable cardiac matrix, or BCM, is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union.
BCM is a medical device intended to prevent congestive heart failure following a STEMI, which is a type of severe heart attack.
BCM is delivered during a minimally invasive, commonly performed cardiac procedure called a percutaneous coronary intervention procedure. BCM is a formulated sterile solution of sodium alginate and calcium gluconate designed to be administered as a liquid through the coronary artery. When administered following a STEMI, BCM flows into damaged heart muscle where, in the presence of abnormally high extracellular calcium released by the damaged cells, it forms a protective hydrogel meshwork within the wall of the heartâ€™s left ventricle. Based on pre-clinical animal studies, we believe that BCM has the potential to act as a flexible scaffold to provide physical support to the ventricle wall in the early stages of recovery following a STEMI and prevent further structural damage while the heart muscle heals. In addition, in our pre-clinical animal studies, as calcium levels in the damaged area returned to normal, BCM dissolved and was excreted through normal kidney function.
IPSCIO Record ID: 368507
U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled â€œCompound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.
Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).
IPSCIO Record ID: 26864
USC File 2651 U.S. Patent Application Serial No. 08/767,221 filed December 16, 1996 (abandoned) entitled 'Cerebral Protection Balloon For Use In Carotid Artery Angioplasty and Stenting'
USC File 2561 U.S. Patent Application Serial No. 08/906,890 filed August 6,1997 (which is a continuation of U.S. Ser. No. 08/767,221), entitled Angioplasty Catheter'.
USC File 2561 PCT Patent Application Serial No. PCT/US97/23257 filed December16, 1997 and corresponding to U.S. Patent Applications Serial Nos. 08/767,221and 08/906,890.
USC File 2639 Invention Disclosure entitled 'New Balloon-Inflated Carotid Artery Stent to Assist in Carotid Artery Balloon Angioplasty'.
IPSCIO Record ID: 27250